Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Rahnamoun, Homa ^a   Lu, Hanbin ^a   Duttke, Sascha H ^b   Benner, Christopher ^b   Glass, Christopher K ^b,c   Lauberth, Shannon M ^a  

^a SECTION OF MOLECULAR BIOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53; RNA POLYMERASE II; PROTEIN BINDING; TUMOR NECROSIS FACTOR;

CANCER; CELLS AND CELL COMPONENTS; GENE; GENE EXPRESSION; GENETIC ANALYSIS; IMMUNE SYSTEM; PROTEIN; RNA; TUMOR;

ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; ENHANCER REGION; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR PROMOTION; GENETICS; IMMUNOLOGY; MUTATION; NEOPLASM; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL LINE, TUMOR; ENHANCER ELEMENTS, GENETIC; HUMANS; MUTATION; NEOPLASMS; NF-KAPPA B; PROTEIN BINDING; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85030318071     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01117-y     Document Type: Article

References (39)

1. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 12, 715-723 (2011).
2. Natoli, G. NF-kappaB and chromatin: ten years on the path from basic mechanisms to candidate drugs. Immunol. Rev. 246, 183-192 (2012).
3. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
4. Beckerman, R. & Prives, C. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2, a000935 (2010).
5. Cooks, T. et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634-646 (2013).
6. Di Minin, G. et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol. Cell 56, 617-629 (2014).
7. Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317 (2014).
8. Di Agostino, S. et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10, 191-202 (2006).
9. Barish, G. D. et al. Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. Genes Dev. 24, 2760-2765 (2010).
10. Biddie, S. C. et al. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol. Cell 43, 145-155 (2011).
11. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
12. Lefterova, M. I. et al. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol. Cell Biol. 30, 2078-2089 (2010).
13. Mullen, A. C. et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell 147, 565-576 (2011).
14. Nielsen, R. et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 22, 2953-2967 (2008).
15. Trompouki, E. et al. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 147,577-589 (2011).
16. Chepelev, I., Wei, G., Wangsa, D., Tang, Q. & Zhao, K. Characterization of genome-wide enhancer-promoter interactions reveals co-expression of interacting genes and modes of higher order chromatin organization. Cell Res. 22, 490-503 (2012).
17. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
18. Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007).
19. De Santa, F. et al. A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol. 8, e1000384 (2010).
20. Hah, N. et al. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145, 622-634 (2011).
21. Kim, T. K. et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 465, 182-187 (2010).
22. Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120-124 (2011).
23. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286 (2012).
24. John, S. et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 43, 264-268 (2011).
25. Do, P. M. et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 26, 830-845 (2012).
26. Zhu, J. et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206-211 (2015).
27. Lee, D. H. & Goldberg, A. L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403 (1998).
28. Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
29. Heinz, S., Romanoski, C. E., Benner, C. & Glass, C. K. The selection and function of cell type-specific enhancers. Nat. Rev. Mol Cell Biol. 16,144-154 (2015).
30. Weisz, L., Oren, M. & Rotter, V. Transcription regulation by mutant p53. Oncogene 26, 2202-2211 (2007).
31. Core, L. J., Waterfall, J. J. & Lis, J. T. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322, 1845-1848 (2008).
32. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25, 402-408 (2001).
33. Borodina, T., Adjaye, J. & Sultan, M. A strand-specific library preparation protocol for RNA sequencing. Methods Enzymol. 500,79-98 (2011).
34. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
35. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
36. Tripathi, S. et al. Meta- and orthogonal integration of influenza "OMICs" data defines a role for UBR4 in virus budding. Cell Host Microbe 18, 723-735 (2015).
37. Lauberth, S. M., Bilyeu, A. C., Firulli, B. A., Kroll, K. L. & Rauchman, M. A phosphomimetic mutation in the Sall1 repression motif disrupts recruitment of the nucleosome remodeling and deacetylase complex and repression of Gbx2. J. Bio. Chem. 282, 34858-34868 (2007).
38. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
39. Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nuc eic Acids Res. 44, W160-W165 (2016).